下記の通り創薬科学セミナー(先端薬科学特論単位認定講義・GTR / CIBoG共催)
を開催します。(発表言語:英語)
Jonghoon Choi博士は、若手のBiomedical Engineeringを牽引するRising Starの一人で、
極めて精力的に医療診断のためのナノバイオ粒子の創成研究を進めています。
今回、ナノ粒子サイエンスの先端についてご講演いただきます。
多数のご参加をお待ちしております。
先端薬科学特論としての単位認定が必要な方は、
下記URLのGoogle Formよりお申込みをお願いします。
講演の聴講のみの場合
⇨ Zoomミーティングに参加する
ミーティングID: 849 9675 6149
パスコード: 262405
For international GTR students:
Please send your report from the following Google Form:
DEADLINE: 4 Jan 2022 23:00PM
概要 | Lectin-glycan affinity in nanobio theragnostics: The specific capture of pancreatic cancer exosomes and the targeted therapy of tumor cells. (in English) |
---|---|
日時 | 2021年12月21日火曜日・17:00~18:30 |
場所 | Zoom開催 |
講師 | Dr. Jonghoon Choi(School of Integrative Engineering at Chung-Ang University/Associate Professor) |
連絡先 | 加藤 竜司(kato-r@ps.nagoya-u.ac.jp) |
ファイル | 1639454397Souyaku_seminar_146_DrJonghoonChoi.pdf |
ABSTRACT:
The unique profile of upregulated glycosylation in metastatic cancer cells may form the basis for the development of new biomarkers for the targeting and diagnosis of specific cancers. This study introduces a pancreatic cancer cell-derived exosome detection technology, which is based on the specific binding of lectins to distinctive glycan profiles on the surface of exosomes. Lectins with a high and specific affinity for sialic acid or fucose were attached to bifunctional Janus nanoparticles (JNPs), which facilitated interactions with pancreatic cancer cell-derived exosomes in a microfluidic device.
Here, we show that pancreatic cancer cell-derived exosomes from two cell lines and plasma samples collected from patients diagnosed with pancreatic cancer were successfully captured on the lectin-conjugated JNPs with affinities that were comparable to those of CA19-9, a conventional antibody. In addition, exosome detection using our platform could differentiate between metastatic and nonmetastatic pancreatic cancer cells. The lectin affinity to surface glycan of cancer cells can also be the strategy to target tumor with lectin-nanoparticles in photothermal therapy. This study opens the possibility to achieve a new early diagnosis marker and targeting moiety based on the glycan properties of pancreatic cancer cells.
The unique profile of upregulated glycosylation in metastatic cancer cells may form the basis for the development of new biomarkers for the targeting and diagnosis of specific cancers. This study introduces a pancreatic cancer cell-derived exosome detection technology, which is based on the specific binding of lectins to distinctive glycan profiles on the surface of exosomes. Lectins with a high and specific affinity for sialic acid or fucose were attached to bifunctional Janus nanoparticles (JNPs), which facilitated interactions with pancreatic cancer cell-derived exosomes in a microfluidic device.
Here, we show that pancreatic cancer cell-derived exosomes from two cell lines and plasma samples collected from patients diagnosed with pancreatic cancer were successfully captured on the lectin-conjugated JNPs with affinities that were comparable to those of CA19-9, a conventional antibody. In addition, exosome detection using our platform could differentiate between metastatic and nonmetastatic pancreatic cancer cells. The lectin affinity to surface glycan of cancer cells can also be the strategy to target tumor with lectin-nanoparticles in photothermal therapy. This study opens the possibility to achieve a new early diagnosis marker and targeting moiety based on the glycan properties of pancreatic cancer cells.